Figure 2.

Representative Western Blot of CYP2C8, CYP2C9, CYP2D6, CYP3A4, villin and glyceraldehyde 3-phosphate dehydrogenase in six healthy subjects before and during rifampicin administration. (–) lanes: before rifampicin intake (+) lanes: during rifampicin intake (600 mg d⁻¹ for 10 d). Calibration samples of recombinant CYP2C8, CYP2C9, CYP2D6 and CYP3A4 were used for quantification. For controlling the cross activity of the CYP2C8 and CYP2C9 antibodies, the last three lanes of the CYP2C8 and CYP2C9 blots were loaded with recombinant CYP2C9, CYP2C18, CYP2C19 and CYP2C8, CYP2C18, CYP2C19, respectively. Subject 1 was a carrier of the CYP2D6*4/*4 genotype, and therefore no protein was detectable